4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alphamab Oncology (9966) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 515 employees. Its market capitalization is roughly HK$8 billion. In the fiscal year ended 2025-12-31, 9966 reported CNY 566M in revenue and (CNY 114M) in net income.
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China.
Interactive charts & full statements → Open the 9966 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 566M | CNY 640M | CNY 219M | CNY 167M | — |
| Gross Profit | CNY 503M | CNY 580M | CNY 164M | CNY 123M | — |
| Operating Income (EBIT) | (CNY 136M) | CNY 114M | (CNY 306M) | (CNY 408M) | — |
| Net Income | (CNY 114M) | CNY 166M | (CNY 211M) | (CNY 326M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 2.1B | CNY 2.2B | CNY 2.1B | CNY 2.1B | — |
| Total Liabilities | CNY 386M | CNY 410M | CNY 465M | CNY 560M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9966 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms